Novartis agreed to acquire a Synnovation unit for an upfront payment of $2 billion to secure a next‑generation PI3Kα inhibitor program aimed at HR+/HER2‑ breast cancer. The asset, SNV4818, is designed to selectively inhibit mutant PI3Kα to reduce on‑target wild‑type toxicity that limits current therapies. Company statements indicate the drug is in early clinical testing, with primary study completion dates into 2027. Analysts and company spokespeople framed the deal as a bid to improve tolerability and expand combinability versus existing PI3Kα agents such as alpelisib. Novartis flagged plans to accelerate development into earlier lines if safety and selectivity meet expectations. The purchase adds to a recent industry wave of buyouts for mutation‑selective small molecules. This transaction shifts competitive positioning in PI3Kα oncology programs and increases pressure on incumbents to demonstrate differentiated safety profiles while moving next‑gen candidates into combination and earlier‑line trials.